Inflamed-HLH, MAS, or something else?

Area of Science:

• Pediatric Hematology
• Immunology
• Critical Care Medicine

Background:

• Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome.
• Primary HLH predominantly affects young children and requires prompt diagnosis and treatment to prevent multiorgan failure and death.
• Current diagnostic criteria (HLH-2004) lack specificity, leading to potential misdiagnosis in other inflammatory conditions.

Purpose of the Study:

• To propose a diagnostic pathway for distinguishing primary HLH from other pro-inflammatory states.
• To aid clinicians in accurately identifying HLH and initiating appropriate disease-specific therapy.
• To reduce the risk of catastrophic outcomes associated with improper HLH treatment.

Main Methods:

• Development of a structured diagnostic algorithm for patients with suspected HLH.
• Emphasis on reevaluation for occult conditions (malignancy, infection, rheumatologic disease) when initial workup is inconclusive.
• Consideration of temporizing medications for critically ill patients during diagnostic evaluation.

Main Results:

• The proposed pathway aims to improve the reliability of primary HLH diagnosis.
• It facilitates differentiation from other conditions that may mimic HLH.
• Enables timely initiation of targeted, disease-specific therapies.

Conclusions:

• Accurate differentiation of primary HLH is crucial due to the severe consequences of misdiagnosis and inappropriate treatment.
• The proposed diagnostic framework supports clinicians in making more reliable diagnostic decisions.
• This approach promotes timely and appropriate disease-specific management for patients with HLH.